BEIJING (Reuters) – U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China’s medical products administration.
The vaccine has been cleared to be used for males aged 9-26 years, according to Merck’s statement on Chinese social media.
(Reporting by Beijing Newsroom; Editing by Tom Hogue)
